1. Home
  2. SXC vs PRTA Comparison

SXC vs PRTA Comparison

Compare SXC & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SunCoke Energy Inc.

SXC

SunCoke Energy Inc.

HOLD

Current Price

$6.59

Market Cap

508.8M

Sector

Industrials

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$9.26

Market Cap

501.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SXC
PRTA
Founded
1960
2012
Country
United States
Ireland
Employees
848
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
508.8M
501.2M
IPO Year
2011
2013

Fundamental Metrics

Financial Performance
Metric
SXC
PRTA
Price
$6.59
$9.26
Analyst Decision
Hold
Buy
Analyst Count
1
9
Target Price
$9.00
$19.00
AVG Volume (30 Days)
1.9M
496.3K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
7.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,600,300,000.00
$814,000.00
Revenue This Year
N/A
$1,111.38
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.30
N/A
52 Week Low
$5.52
$4.32
52 Week High
$9.82
$12.20

Technical Indicators

Market Signals
Indicator
SXC
PRTA
Relative Strength Index (RSI) 53.48 51.98
Support Level $6.57 $9.07
Resistance Level $6.97 $9.59
Average True Range (ATR) 0.29 0.38
MACD 0.13 0.03
Stochastic Oscillator 80.49 64.30

Price Performance

Historical Comparison
SXC
PRTA

About SXC SunCoke Energy Inc.

SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: